Stock Track | CARsgen-B Soars 6.01% Intraday on Positive CAR-T Therapy Milestones

Stock Track05-13

CARsgen-B's stock price surged 6.01% during intraday trading on Wednesday, driven by positive updates on the company's clinical pipeline.

The movement follows the company's disclosure of multiple research milestones for its CAR-T therapies. Key developments include Phase Ib clinical trial results for its Claudin18.2-targeting autologous CAR-T product, Satricabtagene Autoleucel, in adjuvant treatment for pancreatic cancer, presented at the ESMO Annual Meeting. Furthermore, research abstracts for two allogeneic CAR-T candidates, CT0596 (targeting BCMA) and CT1190B (targeting CD19/CD20), developed on its proprietary THANK-u Plus platform, have been accepted for poster presentation at the European Hematology Association Annual Meeting. The company has announced plans to initiate Phase Ib clinical trials for these candidates, indicating clear advancement in its development timeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104921269?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 09:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104921269","market":"hk","top_or_hot":-1,"title":"Stock Track | CARsgen-B Soars 6.01% Intraday on Positive CAR-T Therapy Milestones","media":"Stock Track","content":"<p>CARsgen-B's stock price surged 6.01% during intraday trading on Wednesday, driven by positive updates on the company's clinical pipeline.</p><p>The movement follows the company's disclosure of multiple research milestones for its CAR-T therapies. Key developments include Phase Ib clinical trial results for its Claudin18.2-targeting autologous CAR-T product, Satricabtagene Autoleucel, in adjuvant treatment for pancreatic cancer, presented at the ESMO Annual Meeting. Furthermore, research abstracts for two allogeneic CAR-T candidates, CT0596 (targeting BCMA) and CT1190B (targeting CD19/CD20), developed on its proprietary THANK-u Plus platform, have been accepted for poster presentation at the European Hematology Association Annual Meeting. The company has announced plans to initiate Phase Ib clinical trials for these candidates, indicating clear advancement in its development timeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CARsgen-B Soars 6.01% Intraday on Positive CAR-T Therapy Milestones</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CARsgen-B Soars 6.01% Intraday on Positive CAR-T Therapy Milestones\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-13 09:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARsgen-B's stock price surged 6.01% during intraday trading on Wednesday, driven by positive updates on the company's clinical pipeline.</p><p>The movement follows the company's disclosure of multiple research milestones for its CAR-T therapies. Key developments include Phase Ib clinical trial results for its Claudin18.2-targeting autologous CAR-T product, Satricabtagene Autoleucel, in adjuvant treatment for pancreatic cancer, presented at the ESMO Annual Meeting. Furthermore, research abstracts for two allogeneic CAR-T candidates, CT0596 (targeting BCMA) and CT1190B (targeting CD19/CD20), developed on its proprietary THANK-u Plus platform, have been accepted for poster presentation at the European Hematology Association Annual Meeting. The company has announced plans to initiate Phase Ib clinical trials for these candidates, indicating clear advancement in its development timeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1104921269","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104921269","pubTimestamp":1778636632,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CARsgen-B's stock price surged 6.01% during intraday trading on Wednesday, driven by positive updates on the company's clinical pipeline.The movement follows the company's disclosure of multiple...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"个股追踪|CAR-T疗法里程碑利好科济安-B盘中大涨6.01%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"CARsgen-B's stock price surged 6.01% during intraday trading on Wednesday, driven by positive updates on the company's clinical pipeline.The movement follows the company's disclosure of multiple research milestones for its CAR-T therapies. Key developments include Phase Ib clinical trial results for its Claudin18.2-targeting autologous CAR-T product, Satricabtagene Autoleucel, in adjuvant treatment for pancreatic cancer, presented at the ESMO Annual Meeting. Furthermore, research abstracts for two allogeneic CAR-T candidates, CT0596 (targeting BCMA) and CT1190B (targeting CD19/CD20), developed on its proprietary THANK-u Plus platform, have been accepted for poster presentation at the European Hematology Association Annual Meeting. The company has announced plans to initiate Phase Ib clinical trials for these candidates, indicating clear advancement in its development timeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104921269","isCrawlerRequest":true}